| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 241 |
| 1 | CARBOPLATIN | 136 |
| 2 | NIRAPARIB | 128 |
| 3 | DEXAMETHASONE | 108 |
| 4 | DEXAMETHASONE 1.5 MG | 108 |
| 5 | BEVACIZUMAB | 94 |
| 6 | RIBOCICLIB | 90 |
| 7 | PACLITAXEL | 88 |
| 8 | DURVALUMAB | 74 |
| 9 | PACLITAXEL (AIBUMIN-BOUND) | 73 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | LOMUSTINE | 27 | 0.0104 |
| 1 | TAFASITAMAB-CXIX | 9 | 0.0099 |
| 2 | NIRAPARIB | 128 | 0.0058 |
| 3 | ENASIDENIB MESYLATE | 16 | 0.0047 |
| 4 | DURVALUMAB | 74 | 0.0034 |
| 5 | TREMELIMUMAB | 15 | 0.0034 |
| 6 | ENFORTUMAB VEDOTIN | 22 | 0.0028 |
| 7 | RIBOCICLIB | 90 | 0.0028 |
| 8 | ADO-TRASTUZUMAB EMTANSINE | 21 | 0.0025 |
| 9 | TEMOZOLOMIDE | 49 | 0.0023 |
| # | Drug class | Count |
|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 290 |
| 1 | Platinum-based Drug [EPC] | 195 |
| 2 | Corticosteroid [EPC] | 170 |
| 3 | Kinase Inhibitor [EPC] | 154 |
| 4 | Alkylating Drug [EPC] | 115 |
| 5 | Aromatase Inhibitor [EPC] | 113 |
| 6 | Microtubule Inhibitor [EPC] | 107 |
| 7 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 95 |
| 8 | Nucleoside Metabolic Inhibitor [EPC] | 88 |
| 9 | Nonsteroidal Anti-inflammatory Drug [EPC] | 80 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Macrolide Antibacterial [EPC] | 5 | 0.0049 |
| 1 | Programmed Death Ligand-1 Blocker [EPC] | 76 | 0.0035 |
| 2 | Interleukin-6 Antagonist [EPC] | 2 | 0.0031 |
| 3 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 290 | 0.0029 |
| 4 | Interleukin-5 Antagonist [EPC] | 2 | 0.0029 |
| 5 | Estrogen Receptor Antagonist [EPC] | 55 | 0.0014 |
| 6 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 2 | 0.0013 |
| 7 | CD38-directed Cytolytic Antibody [EPC] | 7 | 0.0012 |
| 8 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 10 | 0.0011 |
| 9 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 7 | 0.0011 |